Table 1.
Demographic, clinical, and selected echocardiography date in subgroups separated according to prognosis
| A | B | C | D | |
|---|---|---|---|---|
| Survivors | HT | Death | HT or death | |
| n = 69 | n = 15 | n = 25 | n = 40 | |
| Sex (female), n (%) | 10 | 2 | 4 | 6 |
| (14.5) | (13.3) | (16) | (15.0) | |
| Age (years) | 49.39 | 49.06 | 50.30 | 49.44 |
| (37.56–56.51) | (42.99–54.76) | (36.45–87.90) | (38.58–57.90) | |
| BMI (kg/m2) | 28.37 | 25.53AA | 27.68 | 25.83AA |
| (25.78–31.35) | (21.81–26.65) | (23.77–29.70) | (22.64–29.05) | |
| NYHA class I–II/III–IV (%) | 51/18 | 4/11AAA | 15/10 | 19/21AA |
| (73.9/26.1) | (26.6/73.4) | (60.0/40.0) | (47.5/52.5) | |
| Disease duration (years) | 3.21 | 5.59A | 3.19 | 4.36 |
| (1.38–6.15) | (4.05–9.36) | (0.76–5.51) | (1.71–6.15) | |
| ICD, n (%) | 23 | 7 | 3 | 10 |
| (20.9) | (46.7) | (12.0) | (25.0) | |
| HA, n (%) | 20 | 2 | 7 | 9 |
| (29.0) | (13.3) | (28.0) | (22.5) | |
| DM t. 2, n (%) | 8 | 1 | 2 | 3 |
| (11.6) | (6.7) | (8.0) | (7.5) | |
| Sinus rhythm, n (%) | 55 | 12 | 21 | 33 |
| (79.7) | (80.0) | (84.0) | (82.5) | |
| Atrial fibrillation, n (%) | 14 | 3 | 4 | 7 |
| (20.3) | (20.0) | (16.0) | (17.5) | |
| LVEF (%) | 25.00 | 20.00AA | 20.00A | 20.00AAA |
| (20.00–30.00) | (15.00–21.00) | (15.00–26.00) | (15.00–25.00) | |
| LVEDV (ml) | 185.0 | 219.0 | 238.0A | 229.0A |
| (153.0–240.0) | (181.5–265.0) | 170.0–297.0) | (178.0–270.0) | |
| LVEDD (mm) | 68.00 | 73.00A | 69.00 | 71.00 |
| (62.00–74.00) | (68.00–78.50) | (62.00–80.00) | (65.00–80.00) |
HT heart transplant, BMI body mass index, NYHA class New York Heart Association functional class, ICD implantable cardioverter-defibrylator, HA arterial hypertension, DM t.2 diabetes t. 2, LVEF left ventricle ejection fraction, LVEDV left ventricle end-diastolic volume, LVEDD left ventricle end-diastolic diameter
Statistic significance: Ap < 0.05, AAp < 0.01, AAAp < 0.001 when compared to A group